Marta Gabasa

SERUM BIOMARKERS IN INTERSTITIAL LUNG ABNORMALITIES AND FAMILIAL EARLY INTERSTITIAL LUNG DISEASE

Elsie Vera-Santiesteban, Marta Gabasa, Yasmina Gutiérrez-Rodríguez, Jose Palma-Rodríguez et autres

Interstitial lung abnormalities (ILA) are incidental findings at thorax computed tomography in asymptomatic patients that could progress and could be sporadic (ILA) or with a genetic substrate (EARLY interstitial lung disease (ILD)). The aim of this study was to analyse serum biomarkers …

es (code pays fourni par la source)

Serum biomarkers in ILA and familial Early ILD.

Elsie Vera-Santiesteban, Marta Gabasa, Yasmina Gutiérrez-Rodríguez, Josep Palma-López et autres

Introduction: Interstitial lung abnormalities(ILA) are incidental findings at thorax computed tomography in asymptomatic patients that could progress and could be sporadic (ILA) or with a genetic substrate(EARLY interstitial lung disease(ILD)). Aims: The aim of this study was to analyze serum biomarkers and …

es (code pays fourni par la source)

Aberrant TIMP ‐1 production in tumor‐associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma

Paula Duch, Natalia Díaz‐Valdivia, Marta Gabasa, Rafael Ikemori et autres

The fibrotic tumor microenvironment is a pivotal therapeutic target. Nintedanib, a clinically approved multikinase antifibrotic inhibitor, is effective against lung adenocarcinoma (ADC) but not squamous cell carcinoma (SCC). Previous studies have implicated the secretome of tumor-associated fibroblasts (TAFs) in the selective effects …

es, us, at (code pays fourni par la source)

Abstract 2356: Aberrant TIMP-1 secretion by tumor-associated fibroblasts is a major contributor to the selective positive response to nintedanib in lung adenocarcinoma

Paula Duch, Natalia Díaz‐Valdivia, Marta Gabasa, Rafael Ikemori et autres

Abstract Adenocarcinoma (ADC) and Squamous Cell Carcinoma (SCC) are the most frequent histologic subtypes of lung cancer, and both are rich in activated/myofibroblast-like tumor-associated fibroblasts (TAFs). Nintedanib is a potent antifibrotic drug that targets the tumor stroma and is clinically approved to …

es, at, us (code pays fourni par la source)

Data from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Abstract The tumor-promoting fibrotic stroma rich in tumor-associated fibroblasts (TAF) is drawing increased therapeutic attention. Intriguingly, a trial with the antifibrotic drug nintedanib in non–small cell lung cancer reported clinical benefits in adenocarcinoma (ADC) but not squamous cell carcinoma (SCC), even though …

Supplementary Material from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Supplementary Material

Supplementary Figures from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Supplementary Figures S1-S7

Supplementary Tables from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Supplementary Tables

Supplementary Tables from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Supplementary Tables

Supplementary Figures from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Supplementary Figures S1-S7

Supplementary Material from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Supplementary Material

Data from Epigenetic SMAD3 Repression in Tumor-Associated Fibroblasts Impairs Fibrosis and Response to the Antifibrotic Drug Nintedanib in Lung Squamous Cell Carcinoma

Rafael Ikemori, Marta Gabasa, Paula Duch, Miguel Vizoso et autres

Abstract The tumor-promoting fibrotic stroma rich in tumor-associated fibroblasts (TAF) is drawing increased therapeutic attention. Intriguingly, a trial with the antifibrotic drug nintedanib in non–small cell lung cancer reported clinical benefits in adenocarcinoma (ADC) but not squamous cell carcinoma (SCC), even though …